Employees: 83
Size Kitazato (368A.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $317M, the 1324th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,289 on 18 Nov 2026.
Performance Over six months the shares gained 6.9%, against -22.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 9.3% over the last twelve months (peer median +2.5%); the operating margin is 52.1% (peer median -1.9%).
Valuation It trades at 12.2× forward earnings against a peer median of 24.9× (cheapest of 4).
Price implies For today's price to make sense, revenue must grow about -17% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -22 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 56.4 points above its cost of capital (5.1% WACC).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥11.7B | ¥10.9B | ¥10.3B | ¥10.1B | ¥9.35B |
| Revenue growth | — | +6% | +2% | +8% | — |
| Gross profit | ¥7.53B | ¥7.21B | ¥6.97B | ¥7.04B | ¥6.70B |
| EBITDA | ¥6.32B | ¥6.05B | ¥5.96B | ¥6.09B | ¥5.29B |
| Net income | ¥4.12B | ¥3.90B | ¥3.79B | ¥3.97B | ¥3.37B |
| Free cash flow | n/a | ¥3.63B | ¥2.63B | ¥4.42B | ¥2.05B |
| Capital expenditure | n/a | ¥239M | ¥903M | ¥85.0M | ¥80.0M |
| Total debt | ¥39.0M | ¥102M | ¥120M | ¥165M | ¥133M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 368A.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.3% | -6.1% | 10th lowest of 21 |
| 6-month return | +6.9% | -22.1% | 6th highest of 21 |
| Distance from 52-week high | -23.9% | -38.0% | 6th highest of 21 |
| Revenue growth (TTM) | +9.3% | +2.5% | 6th highest of 19 |
| Operating margin | 52.1% | -1.9% | highest of 19 |
| Forward P/E | 12.2× | 24.9× | cheapest of 4 |
| Growth the price implies (Req g, 7 yrs) | -16.8% | 14.3% | least demanding of 12 |
| Growth delivered (Del g) | +5.4% | -0.3% | 6th highest of 12 |
| Hurdle (Req g minus delivered) | -22.2 pp | +17.6 pp | 2nd least demanding of 12 |
| ROIC minus cost of capital | +56.4 pp | -7.7 pp | highest of 18 |
| EV / EBITDA | 5.8× | 15.8× | cheapest of 7 |
| Net debt / EBITDA | -2.2× | -0.6× | 3rd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kitazato 368A.T | Japan | $317M | +7% | +9% | 52% | 12.2× | -16.8% | +5.4% |
| Inovio Pharmaceuticals INO | United States | $317M | +37% | +64% | -25,954% | n/a | n/a | n/a |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $314M | +150% | +66% | 9% | n/a | n/a | n/a |
| Atea Pharmaceuticals AVIR | United States | $320M | -5% | n/a | n/a | n/a | n/a | n/a |
| GC Corp. 005250.KS | South Korea | $321M | -45% | +2% | 3% | n/a | n/a | n/a |
| Swedencare SECARE.ST | Sweden | $321M | -24% | +3% | 7% | 24.9× | 6.1% | +62.1% |
| Chengdu Huasun Technology 000790.SZ | China | $312M | -20% | -36% | -57% | n/a | 27.5% | -6.4% |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $322M | -12% | +6% | -104% | n/a | n/a | n/a |
| Alembic ALEMBICLTD.NS | India | $309M | +25% | -5% | 26% | n/a | 44.3% | +26.7% |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $326M | -39% | +10% | -8% | n/a | n/a | n/a |
| Enwei Pharmaceutical 301331.SZ | China | $308M | -20% | -7% | 5% | n/a | 14.0% | +7.3% |
| Chongqing Hifuture Information Technology 002168.SZ | China | $326M | -27% | +2% | -6% | n/a | 14.3% | -14.0% |
| Hinova Pharmaceuticals 688302.SS | China | $305M | -35% | +251% | -195% | n/a | n/a | n/a |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | -1% | +5% | 22% | n/a | -11.5% | +10.3% |
| Relmada Therapeutics RLMD | United States | $305M | -60% | n/a | n/a | n/a | n/a | n/a |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $333M | -28% | +3% | 6% | n/a | 9.2% | +6.5% |
| Mayne Pharma MYX.AX | Australia | $333M | +155% | -6% | -14% | n/a | 19.0% | -0.9% |
| BioDlink International 1875.HK | Hong Kong | $334M | -24% | -51% | -31% | 288.2× | n/a | n/a |
| Solara Active Pharma Sciences SOLARA.NS | India | $334M | +12% | +27% | 8% | 20.7× | 38.3% | -3.2% |
| Honz Pharmaceutical 300086.SZ | China | $299M | -40% | -23% | -54% | n/a | 56.0% | -12.8% |
| Zhejiang Shengda Bio-Pharm 603079.SS | China | $297M | -30% | -3% | 7% | n/a | 4.6% | -0.3% |